PO.BCS01.02 · 生物信息与计算

以Bulk RNA-seq图谱指导的肿瘤转录组注释

Bulk RNA-seq atlas guided annotation of tumor transcriptomes

海报缩略图:以Bulk RNA-seq图谱指导的肿瘤转录组注释
编号 1417 展板 11 时间 4/20 09:00–12:00 区域 Section 3 主讲 Timmy Wen, MS
分会场 Application of Bioinformatics to Cancer Biology 2
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Timmy T. Wen, Dusan Pesic, Pedro L. Ballester, Josh Nash, Adam Shlien

The Hospital for Sick Children, Toronto, ON, Canada

摘要 Abstract

中文摘要
单细胞RNA测序(scRNA-seq)能够实现细胞异质性的高分辨率分析,揭示新的转录组状态。然而,许多现有的生成式和基础性单细胞模型主要在非肿瘤数据上训练,限制了其在癌细胞注释中的准确性。我们提出SPOTTER(Seed-guided Prediction Of Tumor Transcriptomes with Ensemble Recognition,基于种子引导的集成识别肿瘤转录组预测),这是一个将bulk RNA测序(bulk RNA-seq)癌症图谱与单细胞数据整合的框架。SPOTTER首先使用集成神经网络分类器OTTER(Oncologic TranscripTome Expression Recognition,肿瘤学转录组表达识别)对单个细胞进行分类,该分类器在涵盖超过15,000例儿童和成人癌症样本的分层RACCOON(Resolution-Adaptive Coarse-to-fine Clusters OptimizatiON,分辨率自适应的由粗到细聚类优化)癌症图谱上训练。使用高斯混合模型(GMM)和基于基尼不纯度的OTTER评分过滤来选择高置信度的种子标签,以排除预测不确定的低质量细胞。随后通过scANVI(single-cell Annotation using Variational Inference,使用变分推断的单细胞注释)传播这些标签,实现每个细胞的分类。在九个多样化的儿童和成人单细胞及单核癌症数据集中,SPOTTER可靠地将恶性细胞分配到其预期的肿瘤类别。在具有匹配bulk RNA-seq和单核RNA测序(snRNA-seq)的Ewing肉瘤样本中,SPOTTER在单细胞分辨率下重现了由bulk RNA-seq定义的亚型,区分出一种富集神经元程序(包括SYT1和SOX6)的亚型,以及另一种EWS-FLI1融合活性增加且JAK1信号升高的亚型——这与此前由OTTER和RACCOON在bulk RNA-seq中鉴定的亚型一致。通过整合bulk和单细胞分析,SPOTTER能够表征肿瘤异质性,并支持鉴定亚型特异性标志物,以揭示对某一癌症转录组特征的关键洞见。
查看英文原文 English abstract
Single-cell RNA sequencing (scRNA-seq) enables high-resolution profiling of cellular heterogeneity, revealing novel transcriptomic states. However, many existing generative and foundational single-cell models are trained predominantly on non-neoplastic data, limiting their accuracy in cancer cell annotation. We present SPOTTER (Seed-guided Prediction Of Tumor Transcriptomes with Ensemble Recognition), a framework that integrates bulk RNA sequencing (bulk RNA-seq) cancer atlases with single-cell data. SPOTTER first classifies individual cells using an ensemble neural network classifier OTTER (Oncologic TranscripTome Expression Recognition), trained on the hierarchical RACCOON (Resolution-Adaptive Coarse-to-fine Clusters OptimizatiON) cancer atlas spanning over 15,000 pediatric and adult cancer samples. High-confidence seed labels are selected using a Gaussian mixture model (GMM) and Gini impurity-based filtering of OTTER scores to exclude low-quality cells with uncertain predictions. These labels are then propagated through scANVI (single-cell Annotation using Variational Inference) to achieve per-cell classifications. Across nine diverse pediatric and adult single-cell and single-nucleus cancer datasets, SPOTTER reliably assigned malignant cells to their expected tumor classes. In Ewing sarcoma samples with matched bulk RNA-seq and single-nucleus RNA-seq (snRNA-seq), SPOTTER recapitulated bulk RNA-seq-defined subtypes at single-cell resolution, distinguishing one subtype enriched for neuronal programs, including SYT1 and SOX6 , and another with increased EWS-FLI1 fusion activity and elevated JAK1 signaling-consistent with subtypes previously identified by OTTER and RACCOON in bulk RNA-seq. By integrating bulk and single-cell analyses, SPOTTER enables characterization of tumor heterogeneity and supports identification of subtype-specific markers to reveal critical insights into the transcriptomic profile of a cancer.
利益披露 Disclosure
T. T. Wen, None.. D. Pesic, None.. P. L. Ballester, None.. J. Nash, None. A. Shlien, NewCode Oncology Stock, Patent, Patents filed on RACCOON/OTTER algorithm are licensed to NewCode Oncology. AS is a co-founder of NewCode Oncology.

← 返回 AACR 2026 检索